Aktienanalyse zu Vericel Corp (VCEL)VCELVericel Corp

Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Vericel Corp (VCEL) is a good buy right now due to its strong recent performance and positive growth outlook. The stock has shown a 5-day change of +5.98% and a year-to-date change of +19.43%, indicating strong momentum. Additionally, the company raised its 2026 revenue guidance to between $330 million and $340 million, up from $326 million to $336 million, reflecting confidence in future growth. However, the stock's RSI is at 70.51, suggesting it may be overbought, which could be a risk for short-term investors.

4 analysts cover VCEL: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 57.67.